Denver, CO | April 20, 2026 — AOA Dx today announced the presentation of two new studies at the American Association for Cancer Research (AACR) Annual Meeting 2026, demonstrating significant advancement toward a non-invasive, blood-based test for the early detection of ovarian cancer in women experiencing signs and symptoms. The company is actively preparing for an early access program of the AKRIVIS GD™ Test System, with more data to share soon.

Ovarian cancer remains one of the most challenging cancers to diagnose early, with symptoms that are often vague and overlapping with other conditions. As a result, many women are diagnosed at later stages, when treatment options are limited and outcomes are poor. AOA Dx is defining a new standard in ovarian cancer detection, where clinical concern meets diagnostic certainty, the AKRIVIS GD™ Test System transforms symptoms into an answer, at the moment it matters most.

“The women who need this test are in clinics right now, symptomatic, concerned, and waiting for answers that existing tools weren’t built to give them,” said Oriana Papin-Zoghbi, CEO of AOA Dx. “We have built a platform that meets that moment. The data we are presenting at AACR are a direct reflection of our deliberate, differentiated approach: clinical-grade LC-MS infrastructure purpose-built for multi-omic cancer diagnostics, combined with machine learning that reads across biological systems the way cancer actually behaves. No one else has translated this science to this level of clinical readiness in this population. We have.”

At the core of AOA Dx’s approach is multi-omics, a next-generation method that measures multiple layers of biology simultaneously rather than relying on a single marker. Cancer is not driven by one change alone; it disrupts entire biological systems. By measuring changes across metabolites, lipids, and proteins in the blood, AOA Dx captures a more complete and reliable picture of disease than any single-marker approach can provide. In previously published work in Diagnostics, the AKRIVIS GD™ demonstrated 94.8% sensitivity for early-stage ovarian cancer and 94.4% sensitivity across all stages and subtypes, with strong performance across large, clinically diverse patient cohorts.

The first study presented at AACR — “Translating to Targeted: Bridging Discovery Lipidomics to Multi-Omic Clinical Diagnostic Application in Ovarian Cancer Detection” — represents a defining milestone: AOA Dx has done what no one else has, successfully translating discovery-based lipidomics into a targeted LC-MS assay built for clinical deployment. Analytical precision has been optimized, biological signals are interconnected and locked in, and early-stage ovarian cancer detection performance is maintained in an independent cohort of complex clinical controls, achieving an AUC of 0.92. The study describes AOA Dx’s framework for translating the molecular pathways involved in lipid and metabolite metabolism within the tumor microenvironment into a diagnostic that works in the real world.

The second study — “Reproducible Serum Metabolomics Reveals Consistent Pathway Alterations in Ovarian Cancer Across Independent Cohorts” — establishes the biological foundation powering that diagnostic. Representing the largest serum metabolomics profiling of the symptomatic ovarian cancer population ever conducted, the study analyzed 944 blood samples from women across two independent cohorts in the United States and the United Kingdom. Reproducible metabolic pathway dysregulation in ovarian cancer was demonstrated across both populations, confirming that the biological signals AOA Dx has identified are not artifacts of a single dataset, but reliable, consistent markers of disease that can power a diagnostic answer for the population that needs it urgently.

“The data we are presenting are so exciting because we observe the same metabolic and lipid signals emerge consistently across large, independent patient cohorts,” said Abigail McElhinny, Chief Scientific Officer of AOA Dx. “One poster highlights reproducible metabolomic pathways observed across hundreds of ovarian cancer samples within a complex set of symptomatic controls, while the other poster shows how those biomarker discovery findings can be translated into a targeted blood-based assay. Taken together, these data provide great confidence that our novel biomarker approach reflects the disease biology of ovarian cancer and that we are progressing it to meaningful clinical impact.”

Together, these two posters tell one story: a multi-omic blood test that catches ovarian cancer early in symptomatic women, at clinical grade, in the hands of clinicians who need it now.

Adding to this recognition, AOA Dx’s peer-reviewed article, “Utilizing Serum-Derived Lipidomics with Protein Biomarkers and Machine Learning for Early Detection of Ovarian Cancer in the Symptomatic Population,” was selected by AACR journal editors as part of the cross-journal collection on Prevention and Early Detection featured at the 2026 AACR Annual Meeting. The article was chosen to represent the best of the AACR journals’ content and will be highlighted at the conference.

AOA Dx recently welcomed two senior leaders to accelerate that path. Chris Roberts joins as Chief Product Officer, bringing deep expertise in taking diagnostic platforms from development to commercial scale. Cory Bystrom joins as Senior Director of Biomarker and Analytical Development, a globally recognized expert who has successfully translated LC-MS diagnostics from discovery through clinical deployment. Together, these hires reflect AOA Dx’s deliberate investment in the operational and scientific leadership required to bring a first-of-its-kind multi-omic diagnostic to market.

AOA Dx’s goal is to deliver a simple blood test that reflects the complexity of ovarian cancer biology while remaining practical for clinical use, helping physicians make faster, more informed decisions for women who need answers urgently.

About AOA Dx

AOA Dx is transforming early cancer detection with its proprietary platform, a first-of-its-kind, multi-omics liquid biopsy that integrates lipids, metabolites, proteins and clinical data using advanced machine learning. The company’s lead test, AKRIVIS GD™, is designed to detect ovarian cancer early in symptomatic women, addressing a critical diagnostic gap in one of the deadliest cancers affecting women.

Based in Denver, Colorado, AOA Dx is led by an experienced team of scientists and industry veterans. The lab specializes in multi-omics analysis across lipidomics, metabolomics, and proteomics, powered by high-resolution mass spectrometry. By converting discovery-level data into validated, targeted assays, the platform enables repeatable, clinically scalable diagnostics with strong IP and regulatory pathways.

Media Contact:
Ariel Kramer
Klover Communications
ariel@klovercommunications.com